

Quick Screen Tests Patients' Health Literacy

BY BRUCE JANCIN
Denver Bureau

PHOENIX — Three brief screening questions enable physicians to spot patients lacking the literacy skills necessary to understand and act upon health care information, Lorraine S. Wallace, Ph.D., said at a congress sponsored by the Association for Academic Surgery and the Society of University Surgeons.

"Surgeons should consider administer-

ing these three screening items to identify patients at increased risk of having limited health literacy skills," said Dr. Wallace of the department of family medicine at the University of Tennessee, Knoxville.

According to the Institute of Medicine's landmark 2004 report, "Health Literacy: A Prescription to End Confusion," nearly 50% of English-speaking adults lack the literacy skills needed to adequately use the health care system. The consequences include delayed diagnoses, poor adherence

to medical advice, less use of preventive services, deficient self-management skills, more hospitalizations, and worse short- and long-term health outcomes. By one estimate, the price tag for poor health literacy adds up to \$69 billion per year.

Moreover, last year the Editorial Projects in Education Research Center, supported by the Bill and Melinda Gates Foundation, reported that fully 30% of U.S. ninth graders fail to finish high school with a diploma.

Dr. Wallace noted that more than 800 published studies demonstrate that patient education materials are far too difficult for the average patient to understand. The great majority of this research has been done in primary care settings and has relied upon assessment tools too cumbersome for use in clinical practice.

Despite this large body of evidence, however, limited health literacy "still isn't even on residents' radar screens" at most academic medical centers, Dr. Wallace said. "The first issue for physician educators is to get them to understand that the high school dropout rate across America is 29%. That's who your patient population is."

Dr. Wallace sought to determine whether the screening questions for limited health literacy previously studied in primary care are also accurate in the surgical setting.

The questions were as follows:

► How often do you have someone (like a family member, friend, or hospital worker) help you read hospital materials?

► How confident are you filling out medical forms by yourself?

► How often do you have problems learning about your medical condition because of difficulty understanding written information?

Patients rate their answers to each question on a 1-5 scale.

Dr. Wallace studied 100 adult patients attending a vascular surgery clinic for an initial consultation. None had overt psychiatric illness or severe cognitive impairment. They averaged 62 years of age. Sixty-five were women. Ninety-six were white, reflecting east Tennessee's demographics. Thirty-two hadn't completed high school.

All participants were assessed according to the Rapid Estimate of Adult Literacy in Medicine (REALM), which is considered the accepted standard for evaluating patient literacy skills. Thirty-nine patients scored in the limited or marginal health literacy range.

The area under the receiver operating characteristic curves for each of the three screening questions using REALM scores as the reference standard was 0.83-0.86. That's a favorable result. It indicates these specific questions are effective in identifying patients at greatest risk of limited health literacy.

"These questions are nonthreatening. It's not like asking, 'Can you read?' Studies have shown that patients with limited literacy skills do indeed harbor a tremendous amount of shame. It's information they're not about to offer to anyone, let alone their physician," Dr. Wallace explained.

The audience pressed Dr. Wallace as to what exactly she does differently when the screening questions identify a patient with a problem. She replied that while it's clear the clinical interaction has to be tailored accordingly, "there's not really any hard evidence to date as to what will work, unfortunately."

She and her coinvestigators hope to change that. The study she presented is a part of a larger ongoing patient/surgeon communication project aimed at providing specific physician guidance. ■

BIAFINE®

TOPICAL EMULSION

OrthoNeutrogena

Rx Only

Description

BIAFINE® is a water-based emulsion formulated for the dressing and management of superficial wounds, minor abrasions, dermal ulcers, donor sites, 1st and 2nd degree burns, including sunburns, and radiation dermatitis. When applied properly to a wound, BIAFINE® provides an optimum moist environment for the healing process and isolates the wound from harmful germs and other external contamination.

Indications and Usage

BIAFINE® is indicated for use in:

- Full Thickness Wounds, Pressure Sores, Dermal Ulcers including Lower Leg Ulcers
- Superficial Wounds
- 1st and 2nd Degree Burns, including Sunburns
- Dermal Donor and Graft Site Management
- Radiation Dermatitis
- Minor Abrasions

Contraindications

BIAFINE® is contraindicated for use on bleeding wounds, skin rashes related to food or medicine allergies, and when an allergy to one of the ingredients is known.

Warnings

- In radiation therapy, BIAFINE® may be applied as directed by the treating physician. Do not apply 4 hours prior to a radiation session.
- Do not apply BIAFINE® to dermal grafts until after the graft has successfully taken.
- Keep out of the reach of children.

Precautions and Observations

- For the treatment of any dermal wound, consult a physician. Use BIAFINE® only as directed.
- BIAFINE® is non-toxic, it is for topical use only and should not be ingested or taken internally.
- BIAFINE® does not contain a sunscreen and should not be used prior to extended exposure to the sun.
- The use of BIAFINE® on skin rashes due to allergies has not been studied sufficiently and therefore is not recommended.
- Following the application of BIAFINE® a temporary tingling sensation may occur (10 to 15 minutes).
- If clinical signs of infection are present, appropriate treatment should be initiated. If clinically indicated, use of BIAFINE® may be continued during the anti-infective therapy.
- If condition does not improve within 10-14 days, consult a physician.
- BIAFINE® may dissolve fuchsin when this dye is used to define the margins of the radiation fields to be treated.

Instructions for Use

BIAFINE® is for topical use only as directed by a healthcare professional.

Wounds, Abrasions, Full Thickness Wounds, Dermal Graft Site Management and Donor Site Management

- Wash the affected area(s) with saline, clean water, or a suitable wound cleanser.
- Apply BIAFINE® on and around the affected area(s) in thick layers 1/4 to 1/2 inch thick.
- If applying gauze dressing, moisten the dressing lightly before application.
- Reapply BIAFINE® as described above every 24 to 48 hours or as directed until the wound or lesion has healed fully.
- For donor site management, apply BIAFINE® after skin removal and cover with a moist dressing. Reapply as directed.
- For dermal graft site management, apply BIAFINE® to the graft site only after the graft has taken successfully. BIAFINE® can be washed away with a saline solution or clean water without causing damage to the newly formed tissues.

1st and 2nd Degree Burns, Including Sunburns

- Before application of BIAFINE® to burns, take precaution in removing any clothing in the affected area(s).
- Apply BIAFINE® as soon as possible on and around the affected area(s), in a thick 1/4 to 1/2 inch layer until the skin no longer absorbs the product. A white waxy residue may remain. If pain from the burn persists, apply thinner layers of BIAFINE® until the pain has ceased.
- Continue to apply BIAFINE® until the affected area(s) has healed completely.
- Application of BIAFINE® to the affected area(s) should continue during any subsequent physical therapy treatments.

Radiation Dermatitis

- Apply a generous amount of BIAFINE® three times per day, seven days a week to the treated area(s), gently massaging the area(s) until BIAFINE® is completely absorbed.
- BIAFINE® may be applied as indicated by the treating physician (see **Warnings**).
- Continue to apply BIAFINE® as described above until the skin has fully recovered.
- Do not interrupt applications during the course of radiation therapy, even for one day.
- Do not apply BIAFINE® 4 hours prior to a radiation session.

Ingredients

BIAFINE® contains purified water, liquid paraffin, ethylene glycol monostearate, stearic acid, propylene glycol, paraffin wax, squalane, avocado oil, trolamine/sodium alginate, triethanolamine, cetyl palmitate, methylparaben (sodium salt), sorbic acid (potassium salt), propylparaben (sodium salt), and fragrance.

How Supplied

BIAFINE® is supplied in tubes in the following sizes:

45-gram tube	product code 0062-0205-02
90-gram tube	product code 0062-0205-03

Store at room temperature, do not freeze.

Rx ONLY- Prescription Medical Device: Federal Law restricts this device to sale by or on the order of a physician (or properly licensed practitioner).

Distributed by:
OrthoNeutrogena
DIVISION OF ORTHO-McNEIL PHARMACEUTICAL, INC.
Los Angeles, CA 90045

For additional information: www.biafine.com

Made in France